ETOPOSIDE AND HIGH-DOSE CISPLATIN IN GOOD-RISK PATIENTS WITH ADVANCED SQUAMOUS-CELL CARCINOMA AND ADENOCARCINOMA OF THE LUNG

  • 1 July 1986
    • journal article
    • research article
    • Vol. 70  (7) , 891-892
Abstract
Fifty patients with advanced squamous cell carcinoma and adenocarcinoma of the lung having good prognostic features (performance status .ltoreq. 2; weight loss .ltoreq. 10%; age .ltoreq. 70 years; absence of brain metastases; and no prior treatment) were treated on an outpatient basis with etoposide (120 mg/m2 on Days 1, 3, and 5) and cisplatin (60 mg/m2 on Days 1 and 2) every 21-28 days. One complete response and 14 partial responses were observed, with a median duration of response of 170 days and an overall median survival of 230 days. Toxicity was generally mild. Despite the high-dose cisplatin employed and the choice of patients with favorable prognostic factors in this study, results of this therapy remain disappointing.